Background. Liver transplantation is a costly procedure and its cost is likely driven by both donor and recipient factors. Recently, the recipient model for end-stage liver disease (MELD) score has been correlated with increased posttransplant cost; however, other factors have not been identified. We sought to identify if other donor and recipient factors are associated with increased cost. Methods. One hundred sixty-six liver transplants performed at our center from January 2004 through February 2006 were included in the estimation sample, and the subsequent 75 transplants were used as a validation cohort. To determine whether donor factors influenced cost, two latent class linear regression models were created from the estimation sample: one considering only recipient variables (model A) and a second incorporating both donor and recipient factors (model B). The resultant models were then validated in the second group of patients and compared with the best single-segment linear regression models. Results. Model A predictors include pretransplant intensive care unit (ICU) stay, ageϫbody mass index, and calculated MELD. In model B, significant predictors are calculated MELD, age, ageϫpretransplant ICU stay, and donor age more than 40 as significant variables. In validation, only model A remained predictive of cost. Conclusions. Although marginal donor factors are recognized to influence clinical outcome, they did not factor significantly in cost modeling. In addition to MELD, the recipient factors of pretransplant ICU stay, age, and body mass index are pretransplant variables correlated mostly with posttransplant cost across broad populations.
C ost has become an important component of healthcare policy decisions because of dramatic increases in healthcare expenses in the face of limited financial resources. Liver transplantation has long been identified as a costly but life saving procedure for patients with end-stage liver disease (1) . Improvements in operative strategy, anesthesia, critical care, and immunosuppression have dramatically improved recipient outcomes over the past 2 decades with 1-year patient survival now reported to be 85% (2) . These improvements have translated into a change in allocation policy whereby organs are allocated to those patients with the highest risk of death.
The model for end-stage liver disease (MELD) supplanted the Childs-Turcotte-Pugh and time-based policy of organ allocation in 2002. Model for end-stage liver disease was initially developed to predict survival after transjugular intrahepatic portosystemic shunting; however, it has been found to accurately predict 3-month survival while waiting for liver transplantation (3) . Despite its ability to better predict pretransplant mortality, MELD has not clearly demonstrated the ability to predict posttransplant outcome (4, 5) . Recent data have demonstrated that since implementation of the "sicker patients first" MELD-based allocation policy, the severity of recipient disease, and posttransplant resource usage has increased suggesting costs may be higher (6) .
Recent data demonstrate a significant but poorly correlated association of MELD to increased cost (7) . Other recipient characteristics associated with increased cost have not been identified and the role of donor factors remains undefined. The aim of this study is to identify donor and recipient characteristics associated with cost of liver transplantation in the era of MELD-based allocation. We have found that in addition to MELD, the recipient factors of pretransplant intensive care unit (ICU) hospitalization, age, and body mass index (BMI) are key pretransplant variables correlated with posttransplant cost.
METHODS

Patient Population and Data Acquisition
Approval of the Vanderbilt University Institutional Review Board was obtained before collection of any study data. All adult recipients of whole-organ cadaveric orthotopic liver transplants from January 2004 through February 2006 were used to create an estimation sample for model creation. The subsequent 75 transplants were used as a validation sample for models created from the estimation sample. All transplant events were included with no censoring for early death. Recipient data were collected from the medical record and the prospectively maintained institutional transplant database. Recipient information collected included demographic information, cause of liver disease, pretransplant laboratory data, pretransplant United Network for Organ Sharing status, posttransplant laboratory data, hospital course, and followup information. The listed MELD was obtained for each recipient, however an MELD calculated from the immediate pretransplant laboratory data was used for analysis to more accurately estimate disease severity.
The cause of end-stage liver disease was recorded for each patient; however, specific diagnoses were grouped as (1) viral hepatitis, (2) alcoholic or cryptogenic cirrhosis, (3) cholangiopathy, (4) metabolic liver disease, and (5) others, including non-hepatocellular carcinoma (HCC) tumors, rejection, and hepatic-artery thrombosis. Retransplantation during the same hospitalization was not considered a new transplant event and costs incurred from retransplantation during the index admission were included with those of the original transplant. Donor data including demographics, laboratory data, cause of death, and hospital course were collected from donor records maintained by the center. Posttransplant factors such as length of stay were not included in the model as these factors are in the causal pathway to increased cost. Technical complications such as anastomotic thrombosis or biliary complications certainly contribute to posttransplant cost; however, their occurrence is suggested by increasing severity of recipient disease (8) and inclusion would not allow for creation of models using only pretransplant factors. Recipient complications were defined as any infectious event, rejection, myocardial infarction, arrhythmia, deep venous thrombosis, pulmonary embolus, mechanical ventilation more than 96 hr, reintubation, tracheostomy, intraabdominal fluid collection requiring aspiration or reoperation, bowel obstruction, perforated viscus, bile leak or stricture, vascular complication requiring therapy, reexploration, wound dehiscence, cerebrovascular accident, seizure, gastrointestinal bleeding requiring intervention, early hepatitis C virus reactivation, and acute renal failure requiring dialysis.
Financial Data
Actual hospital cost data were obtained for each transplant event beginning at the time of organ allocation and ending at hospital discharge. Professional fees of physicians including those of the surgeons, anesthesiologists, intensivists, and other consultants were not included. Costs associated with pretransplant hospitalization were not included in the analysis because of care provided at multiple institutions, for example, the Veterans Administration (VA). Only costs directly attributable to the transplant event were used. Recipient and donor evaluations occur before the transplant event and are represented as organ acquisition costs (OAC). Organ acquisition cost is tracked in an account that is set up for each recipient at the initiation of transplant evaluation. All costs incurred during evaluation for that recipient are billed to that account; this includes evaluation costs and allocation of center expenses in addition to the actual cost of the organ. The latter ranged from $25,000 to $30,000 per organ, or half of the total acquisition cost. Once an organ is transplanted, the costs incurred during evaluation of the donor are charged to the recipient account and recovered as part of the contract reimbursement. We have included OAC in our model, because these costs are part of the negotiated contract. Changes in hospital cost because of time were evaluated by comparing mean cost for each 6-month interval within the study period.
Statistical Methods
The primary outcome variable was total direct cost associated with transplant. Univariate analyses of important clinical variables were carried out to identify pretransplant variables that were promising as predictors of cost. Continuous variables were analyzed using Spearman's rho and categorical variables with the Mann-Whitney U or Kruskal-Wallis test. Based on these analyses, a preliminary set of candidate predictors for cost and covariates for classifying patients into groups were selected for latent class (LC) analyses. Additional variables were also chosen, a priori, as candidate variables because they seemed promising in determining risk-status, and these variables were also tried as both predictors and covariates. These included the recipient's gender, diagnosis, and indicator variables for high values for the recipient's age, calculated MELD, donor sodium level, and interactions among these variables. As a starting point for stepwise selection of variables in both model A and model B, the best fitting and best predictive models from best-subsets analyses of single segment models were used. As alternative starting points, all candidate main effects were also tried. In forward steps, interactions were considered for all pairs of significant main effects, followed by additional backward selection, so that generally the final model did not include all of the original main effects. Before selecting the final models, all excluded main effects, and interactions related to promising main effects, were added in forward steps, to see if any further improvement was possible.
In model A, only recipient variables were considered for inclusion. Donor factors were included as candidate predictors and as covariates in a second model (Model B) to evaluate the influence of donor characteristics on posttransplant direct cost. The natural log of cost was used as the dependent variable to provide homoscedastic residuals that were symmetrically distributed around zero. For both model A and model B, backward and forward stepwise procedures were used to select the most promising models, and the "best scientific model" of each type was defined as that model that minimized the average value of Bayesian Information Criterion (9) . All statistical calculations were performed using SPSS 15.0 (SPSS Inc.; Chicago, IL), Latent Gold 4.0 (Statistical Innovations; Belmont, MA), or Minitab 14 (Minitab Inc.; State College, PA) with PϽ0.05 as significant. All P values are two-tailed unless otherwise reported.
Model Validation
To evaluate the performance of the models in populations other than that from which they were derived, both Model A and B were tested as predictive models of cost within the separate validation sample. Each LC model was compared with the best predictive single segment model that used the same candidate predictors. Thus, models A and B were compared with the best predictive regression without donor information (regression A) and the best predictive regression model that includes donor information (regression B).
RESULTS
Recipient Data
During the study period from which the estimation sample was derived 166 cadaveric, whole-organ liver transplants were performed. Five patients were retransplanted during the index admission and the cost of these were included with that of the initial transplant event (patient nϭ161). Twenty-five patients received MELD exemptions by the Regional Review Board, 24 of which were for HCC. Uni- variate analysis of donor and recipient pretransplant data is presented in Table 1 . The study population was predominantly made up of White males. The average age was 52.9 years. The most common indication for liver transplantation was viral hepatitis (46.0%) followed by alcoholic or cryptogenic cirrhosis (23.3%). Median listed and calculated MELD scores were 24.0 and 19.6, respectively. On univariate analysis, calculated MELD (Pϭ0.006), hospitalization in the ICU immediately before transplant (PϽ0.001), pretransplant diagnosis of HCC (Pϭ0.006), and pretransplant length of stay (Pϭ0.039) were associated with increased cost (Table 1) .
Donor Data
The most common cause of donor death was cerebrovascular accident or closed head injury (data not shown). Sixty-three (39.1%) of donors were older than 40 years with the majority being White males. The average length of stay before procurement was 3.0 days. During the study period, the organ procurement organization switched preservation solutions from University of Wisconsin (UW, Belzer) solution to Histidine-Tryptophan-Ketoglutarate (HTK) solution. Seventy-three (44.8%) donors received UW, 66 (40.5) received HTK, and the data were missing for 24 (14.7%). Univariate analysis revealed donor age more than 40 (Pϭ0.002) and preservation solution (HTKϾUW, Pϭ0.027) were associated with increased posttransplant cost ( Table 1) .
Outcome and Survival Data
One-year patient and graft survivals without censoring for early deaths were 86.6% and 81.2%, respectively, during the study period. Outcome data are presented in Table 2 . Mean cold ischemia time was 373.4 min (6 hrs 13 min) and mean total operative time was 235.8 min (3 hrs 56 min). Median estimated blood loss was 2.7 L as determined from the electronic anesthesia record. On average, each recipient experienced two complications posttransplant.
The mean direct cost for transplantation was $110,183Ϯ$79,735 and is listed in Table 3 along with cost subsets and the contribution of each to overall direct cost. However, as is shown in Figure 1 , cost is not normally distributed and central tendency is better represented by a median of $82,936 (IQR $74,228 -$108,604). There were no significant differences in mean cost attributable to time within the study period (Pϭ0.592, analysis of variance). The largest contributor to total cost was OAC (45%).
Model Using Only Recipient Factors (Model A)
Model A was created considering only recipient pretransplant variables. Two disparate cost classes were identified when this LC regression model was fit to 160 cases. They represent an estimated 75.5% (class 1) and 24.5% (class 2) of the population. Mean predicted cost for class 1 (low-cost) was $83,349.68 and $146,517.48 for class 2 (high-cost) to give an average predicted cost of $98,825.78. Significant within class predictors on multivariate analysis include pretransplant ICU stay (PϽ0.001), age ϫBMI (PϽ0.001), and calculated MELD (PϽ0.001) with an R 2 of 52.3% for the model (Table  4) . Pretransplant HCC diagnosis did not remain significant on multivariate analysis. This is likely due to the effect of lower median MELD in patients with a pretransplant diagnosis of HCC. These patients receive exemption scores and once the effect of MELD is controlled in a multivariate model, HCC is no longer significant.
Within class predictors represent variables significantly correlated to cost in the regression equation for each class. No significant covariates predicting class assignment were identified in model A. Nevertheless, the class sizes provide a priori estimates of the class-membership probabilities. Predicted cost is then estimated as a weighted average of the within class predictions, where the weights are the estimated class membership probabilities.
Model Using Both Recipient and Donor Factors (Model B)
Model B included both donor and recipient pretransplant variables for LC regression modeling. The model was fit to 143 cases because of missing data for 18 patients. Two segments representing an estimated 74.9% (class 1) and 25.1% (class 2) of the population were identified. Mean predicted cost for those included in class 1 (low cost) and class 2 (high cost) of model B was $84,440.30 and $155,173.64, respectively. Significant within class predictors in the multivariate model, MELD (PϽ0.001), age (PϽ0.001), ageϫpretransplant ICU stay (PϽ0.001), and donor age more than 40 (PϽ0.001, 
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Model Validation
The validation sample had several different population characteristics than the estimation sample. It has a much higher percentage of VA patients than the estimation sample (47% vs. 28%, Pϭ0.009, among observations where model B can be estimated). There is also a significantly higher proportion of donor ages above 40 in the validation sample (57% vs. 38%, Pϭ0.013, among observations where model B can be estimated), but the actual difference in donor age is relatively small and insignificant (39 vs. 35, Pϭ0.095). The validation sample also has a slightly higher average-calculated MELD than the estimation sample (23 vs. 21, Pϭ0.049). The performance of each model in the validation dataset is presented in Table 5 .
In the validation sample, model A significantly outperforms regression A. Its errors are smaller in absolute terms 62% of the time (PϽ0.05), and the entire distribution of model A errors is shifted toward substantially smaller values relative to those of regression A. Model A's mean and median absolute errors are smaller by $4000, and the difference in median absolute percentage error is 3% (means: 31,000 vs. 35,000; medians: 15,000 vs. 19,000; median absolute percentage error is 17% vs. 20%). Model A, which does not use any donor information, significantly outperforms both of model B and regression B on the validation sample. Moreover, model B did not out-perform regression B in the validation sample. Model B had smaller errors only 39% of the time when compared with regression B (PϭNS) and had a $7000 greater error in absolute terms.
DISCUSSION
Liver transplantation represents the only definitive therapy for patients with end-stage liver disease. Current survival rates are excellent and most patients can expect return to full or near-full functional status (10) . From a clinical standpoint, surgeons recognize that the allocation to sickest first has changed the practice both by way of higher risk patients, and also the need to accept more marginal donors. This higher risk scenario raises the cost. Intuitively, one could make the case that a combination of both donor and recipient factors drive the increased cost.
Donor factors are believed to play a in outcome and better donor-recipient matching is proposed to potentially improve outcome (11, 12) . However, an influence of donor factors on posttransplant cost has not been shown. Previous reports from the NIDDK Liver Transplantation Database Group indicate that donor and recipient age, alcoholic liver disease, severity of liver disease (as determined by ChildsTurcotte-Pugh score), pretransplant ICU care, death, and retransplantation are associated with higher rates of resource usage in the pre-MELD era (13) . A recent report by Washburn et al. (7) has significantly correlated MELD to posttransplant cost, but the fact that this correlation was weak suggests that other factors play a significant role.
In our report, we examined all pretransplant donor or recipient variables to determine which correlated with cost. Certainly, intraoperative and postoperative complications contribute significantly to posttransplant cost. Pretransplant MELD is known to correlate with complications (8) which lead, in turn, to increased cost. In our report, we have identified several factors in addition to MELD including age, BMI, and United network for organ sharing status that are significantly associated with posttransplant cost. The study is limited by modest sample size that precludes meaningful examination of infrequent variables such as extreme donor age (Ͼ60 years) and steatosis more than 50%.
To date, only MELD has been associated with increased cost, though this is a weak correlate. Whether or not and which recipient or donor factors drive cost has not been previously reported. To evaluate this, we used LC regression modeling; this represents a method of model-based cluster analysis to better estimate disparate population segments. We have identified that there are broadly two disparate cost classes after liver transplantation. Not surprisingly, this finding supports the Center for Medicaid and Medicare Services contention of having two DRG payments for liver transplant in 2008. The power of LC regression is that it allows for more accurate overall predictions despite the inability to predict class assignment. Thus, for an individual patient, the overall estimated cost is calculated taking into account both class 1 and 2 membership.
Despite the differences in the estimation and validation populations, model A remained robust with significantly less error that the best single-segment regression model that was actually derived from the validation sample. Although inclusion of donor age improved the ability to predict cost in the estimation sample, the finding was not sustained within a separate validation sample. This indicates that recipient factors are key drivers of cost across broad populations. Appropriately, the recipient factors we have shown to correlate with posttransplant cost are many of the same factors that have been associated with clinical outcome (11, 14) . This is not surprising because outcome measures such as duration of hospitalization have been shown to correlate with cost (15, 16) .
In summary, recipient factors are key pretransplant determinants of posttransplant cost. In addition to MELD, we have shown recipient age, BMI, and pretransplant ICU status identified as cost-predictive and validated in a separate cohort. We have also described the use of LC models to incorporate disparate cost segments into a model that more accurately predicts posttransplant cost across disparate populations. 
